Consistently, miR-205 downregulation in tumor tissues has been associated with poor prognosis in early breast cancer, including within specific breast tumor subtypes, such as TNBC and HER2+ malignances [9,10,11,12]. This evidence concerns the gene ERBB2 and breast cancer.